TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from CanSino Biologics, Inc. Class H ( (HK:6185) ).
CanSino Biologics Inc. has released its unaudited third-quarter financial report for the nine months ending September 30, 2025, showing a significant increase in operating revenue and net profit compared to the previous year. The company’s operating revenue rose by 22.13% to RMB 692.57 million, and net profit attributable to shareholders surged by 842.01% to RMB 14.44 million, indicating strong financial performance and potential positive implications for investors and stakeholders.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, specializing in the development and production of vaccines. The company operates in the pharmaceutical industry, focusing on innovative vaccine solutions to address global health challenges.
Average Trading Volume: 2,081,073
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.13B
See more insights into 6185 stock on TipRanks’ Stock Analysis page.